A pharmacoeconomic evaluation of oral triptans in the treatment of migraine in Italy

Minerva Medica

Volumn 97, Issue 6, 2006, Pages 467-477

  Gori, S ^a   Morelli, N ^a   Acuto, G ^b   Caiola, F ^c   Iudice, A ^a   Murri, L ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Almirall SpA   (Italy)

^c Pharmacoeconomist Consultant   (Italy)

Author keywords

Cost efficacy; Migraine; Triptans

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN; TRIAZOLE DERIVATIVE; TRYPTAMINE DERIVATIVE;

ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; HEALTH CARE UTILIZATION; HUMAN; ITALY; META ANALYSIS; MIGRAINE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THORAX DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; ORAL DRUG ADMINISTRATION; SENSITIVITY AND SPECIFICITY;

ADMINISTRATION, ORAL; COST-BENEFIT ANALYSIS; DECISION TREES; HUMANS; ITALY; MIGRAINE DISORDERS; SENSITIVITY AND SPECIFICITY; TRIAZOLES; TRYPTAMINES;

EID: 33847783413     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Stewart WF, Lipton RB, Celetano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race and other sociodemographic factors. JAMA 1992;267:64-9.
2. Rasmussen BK. Epidemiology and socio-economic impact of headache. Cephalalgia 1999;25:20-3.
3. Stewart WF, Schecther A, Rasmussen BK. Migraine prevalence. A review of population-based studies. Neurology 1994:44 Suppl 4:S17-23.
4. Russell MB, Rasmussen BK, Thorvaldsen P, Olesen J. Prevalence and sex-ratio of the subtypes of migraine. Int J Epidemiol 1995;24:612-8.
5. Osterhaus JT, Townsend RJ, Gandek B, Ware JE. Measuring the functional status of well-being of patients with migraine headache. Headache 1994;34:337-43.
6. World Health Organization. The world heath report 2001 - Mental health: new understanding, new hope. Chapter 2: burden of mental and behavioural disorders. http//www.who.int/whr2001/chapter2/en/index3.htm
7. Lipton RB. Migraine: diagnosis and assessment of disability. Rev Contemp Pharmacother 2000;11:63-73.
8. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine study. Headache 2001;41:646-57.
9. Dahlof C, Edwards C, Toth A. Sumatriptan injection is superior to placebo in the acute treatment of migraine with regard to both efficacy and general well-being. Cephalalgia 1992;125:214-20.
10. Dechant KL, Clissald SP. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the acute treatment of migraine and cluster headaches. Drugs 1992;43:776-98.
11. Perry CM, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs 1998;55:889-922.
12. Visser WH, Jaspers NM, de Vriend RH, Ferrari MD. Risk factor for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996;16:264-9.
13. Millson DS. Rational migraine management: optimising treatment with the triptans. Funct Neurol 2000; 15 Suppl 3:182-91.
14. Deleu D, Hanssens Y. Current and emerging second-generation triptans in acute migraine therapy: a comparative review. J Clin Pharmacol 2000;40:687-700.
15. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-58.
16. Reeder CE, Steadman S, Goldfarb SD. Economic comparison of oral triptans for management of acute migraine: implications for managed care. Am J Manag Care 2002;8 Suppl 3:S80-4.
17. Mannix LK. Efficacy, tolerability, and health care costs of triptans for acute migraine treatment. Headache Q 2002;13:19-24.
18. Wang JT, Barr CE, Goldfarb SD. Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan. Headache 2002;42 Suppl 1:S38-43.
19. Slof J, Badia X, Magaz S, Lainez MJ, Galvan J, Heras J. Cost-efficacy of oral triptans in the treatment of acute migraine. J Med Economics 2005;8:13-29.
20. Williams P, Reeder CE. Cost-efficacy of almogran and rizatriptan in the treatment of acute migraine. Clin Ther 2003;25:2903-19.
21. Kelman L. Using sustained pain free with no adverse events (SNAE), a patient-centered endpoint, to compare the cost efficacy of specific acute migraine therapies. American Headache Society (AHS) 2004, June 10-13, Vancouver.
22. Williams P, Reeder CE. A comparison of the cost-efficacy of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point. J Managed Care Pharm 2004;10:259-65.
23. Gobel H. A comparison of the cost-efficacy of specific acute migraine therapies using composite, patients-centered endpoints in Germany. 15 Migraine Trust Symposium, 2004, September 20-23, London.
24. Raieli V, Raimondo D, Cammalleri R, Camarda R. Migraine headaches in adolescents: a student population-based study in Monreale. Cephalalgia 1995;15:5-12.
25. D'Alessandro R, Benassi G, Lenzi PL, Gamberoni G, Sacquegna T, De Carolis P et al. Epidemiology of headache in the Republic of San Marino. J Neurol Neurosurg Psychiatry 1988;51:21-7.
26. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population-a prevalence study. J Clin Epidemiol 1991;44:1147-57.
27. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia 1992;12:221-8.
28. Henry P, Michel P, Brochet B, Dartigues JF, Tison S, Salamon R. A nationwide survey of migraine in France: prevalence and clinical features in adults. GRIM. Cephalalgia 1992;12:229-37.
29. Tfelt-Hansen P, Block G, Dahlof C, Diener HC, Diener HC, Ferrari MD, Goadsby PJ et al. International Headache Society Clinical Trials Subcommittee Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20:765-86.
30. Prestazioni di assistenza specialistica e ambulatoriale. Decreto Ministeriale 150, 22 luglio 1996.
31. nd ed. Oxford: Oxford University Press; 1997.
32. Drummond MF, Rutten F, Brenna A. Economic evaluation of pharmaceuticals. A European perspective. Pharmacoeconomics 1993;4:173-86.
33. Recchia G, De Carli G. Introduzione alia farmacoeconomia. Milano: OEMF Editions; 1993.
34. Gallagher RM, Kunkel R. Migraine medications attributes important for patients compliance: concerns about side effects may delay treatment. Headache 2003;43:36-44.